Patents Assigned to Universite Paris-Saclay
  • Patent number: 11551749
    Abstract: The present invention relates to a neuromimetic network comprising a set of neurons and a set of synapses, at least one neuron comprising a first stack of superimposed layers, the first stack successively comprising: a first electrode, a first barrier layer made of an electrically insulating material, and a second electrode, the first electrode, the first barrier layer and the second electrode forming a first ferroelectric tunnel junction, at least one synapse comprising a second stack of superimposed layers, the second stack successively comprising: a third electrode, a second barrier layer made of an electrically insulating material, and a fourth electrode, the third electrode, the second barrier layer and the fourth electrode forming a second ferroelectric tunnel junction.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: January 10, 2023
    Assignees: UNIVERSITE PARIS-SACLAY, THALES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Manuel Bibes, Julie Grollier, Vincent Garcia, Nicolas Locatelli
  • Publication number: 20230000801
    Abstract: A freeze-dried powder for preparing a thermogel including: from 1% to 35% of 2-[(3-aminopropyl)amino]ethanethiol or one of its pharmaceutically acceptable salt; from 40% to 85% of one or more poloxamer; and from 0.1% to 20% of one or more carbohydrate compound.
    Type: Application
    Filed: November 24, 2020
    Publication date: January 5, 2023
    Applicants: CLEVEXEL PHARMA, INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SACLAY
    Inventors: Denis BRICOUT, Xiuping WANG-ZHANG, Eric DEUTSCH, Céline CLEMENSON
  • Publication number: 20220411846
    Abstract: A method for predicting the pathogenicity and virulence of a strain of Gram-negative bacteria of the Enterobacteriaceae family, wherein the amount of 2-hydroxymyristate and/or 2-hydroxymyristic acid present in the lipopolysaccharides of the bacteria is identified and measured, the amount of 2-hydroxymyristate and/or 2-hydroxymyristic acid is compared with a reference value, and wherein it is concluded that the strain is virulent if the amount of 2-hydroxymyristate is greater than the reference value. Also, the use of the 2-hydroxymyristic acid ester as a marker of pathogenicity and virulence of a Gram-negative bacterial strain and an in vitro diagnosis kit implementing this marker.
    Type: Application
    Filed: November 19, 2020
    Publication date: December 29, 2022
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ PARIS-SACLAY
    Inventors: Pierre TISSIERES, Luis AUGUSTO, Nadège BOURGEOIS-NICOLAOS, Richard CHABY, Aude BRETON, Florence DOUCET-POPULAIRE
  • Publication number: 20220383083
    Abstract: This method for training a binarized neural network, also called BNN, including neurons, with a binary weight for each connection between two neurons, is implemented by an electronic circuit and comprises: a forward pass including calculating an output vector by applying the BNN on an input vector; a backward pass including computing an error vector from the calculated output vector, and calculating a new value of the input vector by applying the BNN on the error vector; a weight update including computing a product by multiplying an element of the error vector with one of the new value of the input vector, modifying a latent variable depending on the product; and updating the weight with the latent variable; each weight being encoded using a primary memory component; each latent variable being encoded using a secondary memory component having a characteristic subject to a time drift.
    Type: Application
    Filed: May 23, 2022
    Publication date: December 1, 2022
    Applicants: Commissariat à l'énergie atomique et aux énergies alternatives, Centre national de la recherche scientifique, UNIVERSITE PARIS-SACLAY
    Inventors: Tifenn HIRTZLIN, Damien QUERLIOZ, Elisa VIANELLO
  • Patent number: 11458194
    Abstract: The inventors have developed a metastatic 4T1 breast tumor model in BALB/c mice. They have shown that the vaccination with xenogeneic embryonic stem cells in combination with valproic acid (VPA) generates a higher anti-tumoral response against breast cancer and inhibits metastasis development. They established that these responses are achieved only by the addition of valproic acid in the therapeutic regimen in comparison to the use ESCs or iPSCs alone. Thus, the inventors provide a new therapeutic strategy to treat cancers expressing embryonic antigens. Accordingly, the present invention relates to i) a population of pluripotent cells and ii) a compound selected from a group which activates MHC expression, as a combined preparation for use in a method for treating a subject suffering from a cancer, comprising a step of administering simultaneously, separately or sequentially to said subject a therapeutically amount thereof.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: October 4, 2022
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS (APHP), UNIVERSITE PARIS-SACLAY, UNIVERSITE PARIS CITE
    Inventors: Frank Griscelli, Ali Turhan, Annelise Bennaceur Griscelli
  • Publication number: 20220175961
    Abstract: A recombinant adeno-associated virus (AAV) vector that carries a nucleic acid sequence encoding the retinal transcription factor cone-rod homeobox (CRX) for its use in treating CRX-associated IRDs in a subject in need thereof or for use in treating inherited retinal dystrophies caused by hypomorphic mutations in the CRX target genes.
    Type: Application
    Filed: March 9, 2020
    Publication date: June 9, 2022
    Applicants: UNIVERSITE PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, RETINA FRANCE, VARIANT
    Inventors: Jérôme ROGER, Elodie Kim GRELLIER
  • Patent number: 11344586
    Abstract: The present invention provides methods for determining if a patient is likely to benefit from a cancer treatment, by determining if said patient has a gut dysbiosis with an over representation of certain bacterial species. The present invention also provides probiotic strains to improve the efficacy of a cancer treatment, especially chemotherapy, in patients in need thereof.
    Type: Grant
    Filed: April 21, 2020
    Date of Patent: May 31, 2022
    Assignees: INSTITUT GUSTAVE ROUSSY, UNIVERSITE PARIS-SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT
    Inventors: Laurence Zitvogel, Ivo Gomperts Boneca, Patricia Lepage, Sophie Viaud, Romain Daillere
  • Publication number: 20220162266
    Abstract: The present invention relates to a mutant polypeptide comprising the amino acid sequence of the ectodomain of glycoprotein G of a vesicular stomatitis vims (VSV) strain, wherein said ectodomain comprises the amino acid sequence as set forth in SEQ ID NO: 2 or a sequence having at least 50% of identity with the amino acid sequence as set forth in SEQ ID NO: 2, with at least one substitution of an amino acid residue selected from the group consisting of: a) any amino acid residue located from position 421 to position 429 and any amino acid residue located from position 17 to position 25 of SEQ ID NO:2; or b) any amino acid residue located from a position equivalent to position 421 to a position equivalent to position 429 of SEQ ID NO: 2 and any amino acid residue located from a position equivalent to position 17 to a position equivalent to position 25 of SEQ ID NO: 2, after optimal global alignment with SEQ ID NO:2.
    Type: Application
    Filed: March 16, 2020
    Publication date: May 26, 2022
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PARIS SACLAY
    Inventors: Aurélie ALBERTINI, Hélène RAUX, Yves GAUDIN, Franck PEREZ
  • Patent number: 11332566
    Abstract: Disclosed are novel polymers that contain monomer units derived from 4-vinylpyridine and monomer units derived from a co-monomer. The polymers may be complexed with a metal, and linear or crosslinked. Also disclosed are methods for preparing these polymers by radical polymerization, as well as to their use for metal capture in aqueous media, particularly uranium capture in seawater or in final nuclear waste from nuclear power plants.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: May 17, 2022
    Assignee: UNIVERSITE PARIS-SACLAY
    Inventors: Philippe Gérard Roger, Mohamad Maaz, Bilal Nsouli, Tamara Elzein, Nadine Barroca-Aubry, Bénédicte Lepoittevin
  • Publication number: 20220143065
    Abstract: The present inventors have identified an miRNA capable of greatly modulating the inflammatory response induced by Clostridium difficile. They thus propose incorporating this miRNA into a pharmaceutical composition for preventing or reducing the harmful effects of this infection on the bowels of infected patients. This microRNA is miR-27a-5p. Advantageously, this miRNA can be linked to a matrix, incorporated into particles, or conveyed by a vector. It can be administered to infected subjects for therapeutic purposes.
    Type: Application
    Filed: November 8, 2019
    Publication date: May 12, 2022
    Applicants: UNIVERSITE PARIS-SACLAY, ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Imad KANSAU, Hussein KOBEISSY, Cecile LARRAZET, Jean-Christophe MARVAUD
  • Patent number: 11320500
    Abstract: A cryogenic device for cooling an RF coil of a Magnetic Resonance Imaging scanner. The cryogenic device includes: a cryocooler providing a cold source; a solid thermal link; the solid thermal link in thermal contact with the cryocooler; a RF coil holder for holding the RF coil, the RF coil holder being in thermal contact with thermal link; a vacuum chamber enclosing the solid thermal link and the RF-coil holder; a measurement surface, facing the RF coil holder; wherein each one of the cryocooler, the solid thermal link, the RF coil holder and the measurement surface is magnetic material free.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: May 3, 2022
    Assignees: COMMISSARIAT À L'ÉNERGIE ATOMIQUE ET AUX ÉNERGIES ALTERNATIVES, UNIVERSITE PARIS-SACLAY
    Inventors: Gilles Authelet, Marie Poirier-Quinot, Bertrand Baudouy
  • Patent number: 11305983
    Abstract: A hermetic housing is disclosed (10a) for an optoelectronic component (11) or a MEMS device configured to form an enclosure (12) within which a low pressure or vacuum prevails. The hermetic housing includes: an optical window (14) transparent for at least one wavelength of interest (?); and a layer of a getter material (15a) configured to capture gases present in said enclosure and deposited on the optical window opposite the enclosure. This layer of getter material has a thickness (e_t), greater than 60 nanometers, and a porosity (P) in the range from 10 to 70% to satisfy the following relation: (1?P)*e_t<?/2?k with ? corresponding to the at least one wavelength of interest, and k corresponding to the extinction coefficient of the material of the layer of getter material for the at least one wavelength of interest of the optical window.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: April 19, 2022
    Assignees: LYNRED, UNIVERSITE PARIS-SACLAY CENTRE NATIONAL DE LA RECHERCHE, SCIENTIFIQUE (CNRS)
    Inventors: Sylvain Lemettre, David Bunel, Johan Moulin, Alain Bosseboeuf
  • Publication number: 20220042926
    Abstract: A microstrip-type microwave sensor for the measurement of the dielectric properties of a solid or liquid material, constituted by a main line and two connected transmission lines integral at one of their extremities to the main line, the main line and two connected transmission lines being spaced from one another by a slot and being made integral with a substrate. The main line is connected to an electrical circuit by each of its two extremities to inject a sinusoidal signal, and wherein said main line has a width giving it an impedance in the range 50 Ohm, the two connected transmission lines being of the same width and of a length equal to one quarter of the wavelength guided in the substrate, the substrate having a height or thickness giving it flexibility or rigidity, the substrate being applied to a metallic support formed of a layer of metallic material.
    Type: Application
    Filed: December 11, 2019
    Publication date: February 10, 2022
    Applicants: UNIVERSITÉ PARIS-SACLAY, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE LILLE, ASSOCIATION YNCRÉA HAUTS-DE-FRANCE, ECOLE CENTRALE DE LILLE, UNIVERSITÉ POLYTECHNIQUE HAUTS-DE-FRANCE
    Inventors: Etienne HERTH, Christophe LOYEZ, Laurie CALVET
  • Patent number: 11237105
    Abstract: A system for measuring the absorption of a laser radiation by a sample is provided. The system comprises: •(i) a pulsed laser source, suitable for emitting pulses at a repetition frequency fl and arranged so as to illuminate the sample; •(ii) an AFM probe arranged so as to be able to be placed in contact with the region of the surface of the sample on one side, the AFM probe having a mechanical resonance mode at a frequency fm; and •(iii) a detector configured to measure the amplitude of the oscillations of the AFM probe resulting from the absorption of the laser radiation by the region of the surface of the sample, characterized in that it also comprises a translation system designed to displace the sample at a frequency fp.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: February 1, 2022
    Assignees: Centre National De La Recherche Scientifique, Universite Paris-Saclay
    Inventor: Alexandre Dazzi
  • Patent number: 11198706
    Abstract: A Dengue virus Envelope Dimer Epitope (EDE) wherein the EDE: c) spans the polypeptides of a Dengue virus Envelope polypeptide dimer; and/or d) is presented on a dimer of Envelope proteins; and/or c) is formed from consecutive or non-consecutive residues of the envelope polypeptide dimer, wherein the dimer is a homodimer or heterodimer of native and/or mutant envelope polypeptides, from any one or two of DENV-1, DENV-2, DENV-3 and DENV-4.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: December 14, 2021
    Assignees: IMPERIAL COLLEGE INNOVATIONS LIMITED, INSTITUT PASTEUR, UNIVERSITE PARIS-SACLAY
    Inventors: Screaton Gavin, Juthathip Mongkolsapaya, Alexander Rouvinski, Pablo Guardado-Calvo, Giovanna Barba-Spaeth, Stéphane Duquerroy, Marie-Christine Vaney, Felix Augusto Rey
  • Publication number: 20210380920
    Abstract: Microfluidic gas exchange devices may include one or more exchange modules (100), wherein each exchange module includes: a first layer comprising: one or more primary inlets (108); a first capillary network connected to the one or more primary inlets, wherein the first capillary network extends radially outward from at least one of the one or more primary inlets, and wherein the first capillary network includes one or more injection branches (104) and a series of microchannels (106); and one or more primary outlets connected to the first capillary network; and a second layer that includes a semipermeable membrane.
    Type: Application
    Filed: October 25, 2019
    Publication date: December 9, 2021
    Applicants: Centre National de la Recherche Scientifique, UNIVERSITE PARIS-SACLAY
    Inventors: Anne-Marie Haghiri, Lyas Djeghlaf, Julie Lachaux, Alisier Paris, Gilgueng Hwang
  • Patent number: 11187705
    Abstract: The invention relates to a method for labeling specifically living microorganisms in a sample comprising microorganisms, the method comprising the steps of: a) incubating said microorganisms of said sample with at least one modified monosaccharide compound comprising a first reactive chemical group capable to chemically react with a second reactive group, so that a residue bearing said first reactive group is incorporated into such microorganisms, and b) contacting said residue incorporated in the microorganisms, with a labeling molecule comprising a said second reactive group, for generating the chemical reaction of said first reactive group of said residue incorporated within said living microorganisms with said second reactive group of said labeling molecule, resulting in a covalent link, characterized in that the said modified monosaccharide compound has the following formula (I?), or a salt thereof: —X can be O, NH or S, preferably O and NH, and —R1 and R2 can be independently H, OH, NH2, OH and NH2 bein
    Type: Grant
    Filed: May 3, 2016
    Date of Patent: November 30, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'AIX-MARSEILLE, UNIVERSITE PARIS-SACLAY
    Inventors: Sam Dukan, Boris Vauzeilles, Jordi Mas Pons, Aurélie Baron
  • Patent number: 11179449
    Abstract: The invention relates to combinations of peptides carrying T-cell epitopes of the antigen preprocalcitonin, presented by the MHC. These peptides can be used in anti-tumour immunotherapy.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: November 23, 2021
    Assignees: Institut Gustave Roussy, Institut National de la Sante et de la Recherche Medicale, Université Paris-Saclay
    Inventors: Fathia Mami-Chouaib, Aurélie Durgeau
  • Patent number: 11165220
    Abstract: A structure includes a semiconductor support, a semiconductor region overlying the semiconductor support, a silicon nitride layer surrounding and straining the semiconductor region, and a metal foot separating the silicon nitride layer from the semiconductor support. The semiconductor region includes germanium. The semiconductor region can be a resonator of a laser or a waveguide.
    Type: Grant
    Filed: October 19, 2017
    Date of Patent: November 2, 2021
    Assignees: STMicroelectronics (Crolles 2) SAS, Universite Paris-Saclay, Centre National de la Recherche Scientifique
    Inventors: Anas Elbaz, Moustafa El Kurdi, Abdelhanin Aassime, Philippe Boucaud, Frederic Boeuf
  • Publication number: 20210301344
    Abstract: The present application describes and claims a novel method for identifying and stratifying the risk of developing a BK virus nephropathy (“Nx BK-v” below) in patients having undergone a kidney transplant. This method uses an index combining at least three bio-markers: i) the intensity of the anti-BK-v memory T lymphocyte response (memory T lymphocytes which are specific to v, hereinafter “LTm anti-BK-v”), ii) the number of occurrences of incompatibility in the HLA alleles of class I and class II between the donor and the recipient of the graft, taking into account iii) the viral charge of the BK-v virus in the whole blood of the patient. The present method allows a very precise evaluation of the risk of developing an Nx BK-v during the months following the test with the aim of optimising the immuno-suppressive treatment in order to better preserve the transplanted kidney.
    Type: Application
    Filed: June 18, 2019
    Publication date: September 30, 2021
    Applicants: UNIVERSITE PARIS-SACLAY, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Inventors: Yassine TAOUFIK, Antoine DURRBACH, Manon DEKEYSER